Healthy ChildrenNCT06986720
Urdu Translation of Revised High-Level Mobility Assessment Tool (HiMAT) in Healthy Children
An observational study of Healthy Children, run by Riphah International University at 1 site in Pakistan.
Trial summary
The ability to move with ease is labelled as mobility. Limitations in mobility are frequent, recovery of these skills is crucial for physical performance which gives children valuable social possibilities and has long-term advantages for their physical and mental health. Read more about this study
- Who is it for?
- Ages 5 to 12 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Children
- How many people
- 80 participants
- Where
- 1 sitePakistan
- Study dates
- 12 May 2025to 16 Jul 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 12 years
- All sexes
- Healthy volunteers accepted
- Child
Study population: The sample size is 80.
Who may be able to join
- Children with age group 5-12 years
- No condition affecting mobility of children
- Able to understand and follow instruction.
- Can speak \& understand language
Who cannot join
- Children with visual impairments.
- Children with conditions affecting their mobility.
- Children with any history of surgery in the past one year.
- Children with any cardiorespiratory comorbidities.
- Children with muscle strain, ligament sprain or joint laxity in lower extremities.
- Cognition less than 20 on Mini Mental State Examination (MMSE).
- Children with any history of any foot deformity
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Pakistan1 site, 1 recruiting
- Recruiting
Riphah International University
Lahore, Punjab Province, 54000
Muhammad Asif Javed, MS, +923224209422, a.javed@riphah.edu.pk
Imran Amjad, PhD, +9233224390125, imran.amjad@riphah.edu.pk
About this study
Official title: Urdu Translation of Psychometric Properties Analysis of Revised High-Level Mobility Assessment Tool (HiMAT) in Healthy Children
The ability to move with ease is labelled as mobility. Limitations in mobility are frequent, recovery of these skills is crucial for physical performance which gives children valuable social possibilities and has long-term advantages for their physical and mental health. The high-level mobility assessment tool (HiMAT) is a unidimensional performance to measure the degree of high-level mobility in traumatic brain injury patients. The revised HiMAT has been utilised recently in paediatric populations to assess clinical trial outcomes and measure high-level motor skills.
Urdu translation of revised HiMAT will be executed by using forward backwards translation method. Two bilingual translators fluent in both Urdu and English languages will facilitate the researcher in the translation of the tool. This final translated version will be then tested for validity and reliability on all participants of the study. The psychometric properties of the tool will be assessed including reliability, internal consistency, and item discrimination.
Read the detailed description
Following steps will be followed for translation:
- Forward Translation: Two independent translators who spoke Urdu as their native language will conduct initial translation into Urdu (U-HiMAT).
- Synthesis: In this step both translated versions (U1 \& U2) will be synthesized to obtain a common translated version of U-HiMAT. Full Urdu version of scale will be completed.
- Backward Translation: Urdu translated version will be translated back into English by a different team consisting of professional independent bilingual translators.
- Expert Committee: Expert committees consisting of pediatric physical therapists and pediatric clinical practitioners will evaluate and review the difference between a translated version and an original draft. They will create a pre final version for field testing.
- Pre-Final Version Testing:
Pre-final Urdu and English version of scale will be tested on patients. Expert panel will review the findings from this process.
After completion of translation process, psychometric properties of the tool will be analysed.
- Conditions
- Healthy Children
- Keywords
- revised HiMAT, Urdu translation, validation, mobility
What is being measured
The primary outcome is the main question the study is designed to answer.
Revised High Level Mobility Assessment Tool (HiMAT)
HiMAT is a single dimensional inspection of high-level movability for those suffering from TBI. The revised HiMAT comprises of 8 items that evaluate (1) walk forward, (2) walk backwards, (3) walk on toes and (4) walk over obstacle, (5) running, (6) skipping, (7) hopping, and (8) bounding. HiMAT has also been used to assess mobility in children with healthy conditions or suffering from any neurological disorder
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 May 2025
- Study start12 May 2025
- Primary completion28 Jun 2025 (estimated)
- Study completion16 Jul 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Healthy ChildrenStudies of the same condition, open and under way.
- More trials run by Riphah International UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Riphah International University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Shazia Muheen, MS, Principal investigator, Riphah International University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06986720
- Sponsor's protocol ID
- REC/RCR&AHS/24/0729
- Status last verified
- May 2025
- First submitted
- 15 May 2025
- Last updated
- 23 May 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Williams G, Pallant J, Greenwood K. Further development of the High-level Mobility Assessment Tool (HiMAT). Brain Inj. 2010;24(7-8):1027-31. doi: 10.3109/02699052.2010.490517.
PubMed 20545456
Study at a glance
From the registry record, last updated by the sponsor on 23 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Urdu Translation of Psychometric Properties Analysis of Revised High-Level Mobility Assessment Tool (HiMAT) in Healthy Children
- ClinicalTrials.gov ID
- NCT06986720
- Acronym / sponsor ID
- REC/RCR&AHS/24/0729
- Conditions
- Healthy Children
- Keywords
- revised HiMAT, Urdu translation, validation, mobility
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Riphah International UniversityUniversity, hospital or other
- Study start
- 12 May 2025 (actual)
- Primary completion
- 28 Jun 2025 (estimated)
- Study completion
- 16 Jul 2025 (estimated)
- First posted
- 23 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The ability to move with ease is labelled as mobility. Limitations in mobility are frequent, recovery of these skills is crucial for physical performance which gives children valuable social possibilities and has long-term advantages for their physical and mental health. The high-level mobility assessment tool (HiMAT) is a unidimensional performance to measure the degree of high-level mobility in traumatic brain injury patients. The revised HiMAT has been utilised recently in paediatric populations to assess clinical trial outcomes and measure high-level motor skills.
Urdu translation of revised HiMAT will be executed by using forward backwards translation method. Two bilingual translators fluent in both Urdu and English languages will facilitate the researcher in the translation of the tool. This final translated version will be then tested for validity and reliability on all participants of the study. The psychometric properties of the tool will be assessed including reliability, internal consistency, and item discrimination.
Detailed description
Following steps will be followed for translation:
- Forward Translation: Two independent translators who spoke Urdu as their native language will conduct initial translation into Urdu (U-HiMAT).
- Synthesis: In this step both translated versions (U1 \& U2) will be synthesized to obtain a common translated version of U-HiMAT. Full Urdu version of scale will be completed.
- Backward Translation: Urdu translated version will be translated back into English by a different team consisting of professional independent bilingual translators.
- Expert Committee: Expert committees consisting of pediatric physical therapists and pediatric clinical practitioners will evaluate and review the difference between a translated version and an original draft. They will create a pre final version for field testing.
- Pre-Final Version Testing:
Pre-final Urdu and English version of scale will be tested on patients. Expert panel will review the findings from this process.
After completion of translation process, psychometric properties of the tool will be analysed.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 5 to 12 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
- Study population
- The sample size is 80.
Key inclusion criteria (4 listed)
- Children with age group 5-12 years
- No condition affecting mobility of children
- Able to understand and follow instruction.
- Can speak \& understand language
Key exclusion criteria (7 listed)
- Children with visual impairments.
- Children with conditions affecting their mobility.
- Children with any history of surgery in the past one year.
- Children with any cardiorespiratory comorbidities.
- Children with muscle strain, ligament sprain or joint laxity in lower extremities.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Revised High Level Mobility Assessment Tool (HiMAT)
Time frame: 6 months
HiMAT is a single dimensional inspection of high-level movability for those suffering from TBI. The revised HiMAT comprises of 8 items that evaluate (1) walk forward, (2) walk backwards, (3) walk on toes and (4) walk over obstacle, (5) running, (6) skipping, (7) hopping, and (8) bounding. HiMAT has also been used to assess mobility in children with healthy conditions or suffering from any neurological disorder
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 May 2025.
- Background: PubMed 20545456Williams G, Pallant J, Greenwood K. Further development of the High-level Mobility Assessment Tool (HiMAT). Brain Inj. 2010;24(7-8):1027-31. doi: 10.3109/02699052.2010.490517.
- Individual participant dataSharing planned: No
Related trials for Healthy Children
Active, not recruitingObservational study
Electrophysiologic Sleep Phenotyping and Sleep-Dependent Neuro-maturation in Clinical and Healthy Pediatric Populations
Healthy Children, Children With Neurodevelopmental Disorders
RecruitingObservational study
Physical Impairments in Children With Chronic Renal Failure
Chronic Kidney Failure, Chronic Kidney Diseases
RecruitingPhase 1
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children
Seasonal Influenza
RecruitingObservational study
Comparison of Individuals With Primary Ciliary Dyskinesia and Healthy Controls
Primary Ciliary Dyskinesia (PCD)
Active, not recruiting
Pediatric Parenting Support in Flint
Healthy, Family Research
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Shazia Muheen, MS principal investigator
Riphah International University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Healthy Children, run by Riphah International University at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Imran Amjad, PhD (+9233224390125, imran.amjad@riphah.edu.pk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Revised High Level Mobility Assessment Tool (HiMAT) (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06986720, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 May 2025.